Emergent BioSolutions has received a $62.4 million contract modification from the U.S. Department of Health and Human Services (HHS) to supply additional doses of its botulism antitoxin, BAT® (Botulism Antitoxin Heptavalent – Equine). The antitoxin, used to treat exposure to all seven botulinum toxin serotypes (A–G), is part of the U.S. Strategic National Stockpile and supports national biodefense readiness. The award is a modification to an existing 10-year contract. BAT® is derived from equine plasma and carries safety considerations such as risk of allergic reactions and infusion-related effects. The product's efficacy is based on animal studies. Emergent emphasized the importance of this supply in protecting public health and national security.